查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387488

癌症單株抗體市場報告：到2030年的趨勢、預測與競爭分析

Cancer Monoclonal Antibodies Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

癌症單株抗體的趨勢和預測

2030年，全球癌症單株抗體市場預計將達到1,537億美元，2024年至2030年的年複合成長率為12.4%。該市場的主要促進因素是研發活動投資的增加，個人化醫療的增加以及全球癌症發生率的增加。全球癌症單株抗體市場的未來充滿希望，醫院和研究機構市場充滿機會。

癌症單株抗體市場洞察

Lucintel 預測，由於小鼠單株抗體的可負擔性、可用性和生產時間短，預計人源化抗體將在預測期內達到最高成長。

由於癌症盛行率不斷上升和住院患者數量不斷增加，醫院將繼續成為該市場的最大細分市場。

由於對先進治療的認知不斷增強、癌症患病率上升以及該地區主要市場參與企業的存在，預計北美在預測期內仍將是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1.細分市場中最有前途和高成長的機會為何？
  • Q.2.未來哪個細分市場成長較快？理由為何？
  • Q.3.哪些地區未來會出現更快的成長？理由為何？
  • Q.4.影響市場動態的主要因素有哪些？市場的主要挑戰和業務風險是什麼？
  • Q.5.這個市場的商業風險和競爭威脅為何？
  • Q.6.這個市場有哪些新趨勢？理由為何？
  • Q.7.市場客戶需求有何改變？
  • Q.8.該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10.該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去五年發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球癌症單株抗體市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球癌症單株抗體市場趨勢（2018-2023）與預測（2024-2030）
  • 依類型分類的全球癌症單株抗體市場
    • 人性化
    • 人類
    • 嵌合體
    • 小鼠或大鼠
  • 全球癌症單株抗體市場（依應用）
    • 血癌
    • 乳癌
    • 肺癌
    • 黑色素瘤
    • 大腸直腸癌
    • 肝癌
    • 其他
  • 全球癌症單株抗體市場（依最終用途）
    • 醫院
    • 研究機構
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球癌症單株抗體市場（依地區）
  • 北美癌症單株抗體市場
  • 歐洲癌症單株抗體市場
  • 亞太地區癌症單株抗體市場
  • 其他地區癌症單株抗體市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球癌症單株抗體市場成長機會（依類型）
    • 全球癌症單株抗體市場成長機會（依應用）
    • 全球癌症單株抗體市場成長機會（依最終用途）
    • 全球癌症單株抗體市場成長機會（依地區）
  • 全球癌症單株抗體市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球癌症單株抗體市場的產能
    • 全球癌症單株抗體市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie
簡介目錄

Cancer Monoclonal Antibodies Trends and Forecast

The future of the global cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets. The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030 with a CAGR of 12.4% from 2024 to 2030. The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.

A more than 150-page report is developed to help in your business decisions.

Cancer Monoclonal Antibodies by Segment

The study includes a forecast for the global cancer monoclonal antibodies by type, application, end use, and region.

Cancer Monoclonal Antibodies Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Humanized
  • Human
  • Chimeric
  • Murine

Cancer Monoclonal Antibodies Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Cancer
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Liver Cancer
  • Others

Cancer Monoclonal Antibodies Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Research Institutes
  • Others

Cancer Monoclonal Antibodies Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Monoclonal Antibodies Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer monoclonal antibodies companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer monoclonal antibodies companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie

Cancer Monoclonal Antibodies Market Insights

Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.

Within this market, hospitals will remain the largest segment due increasing prevalence of cancer along with growing number of patient hospitalizations.

North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.

Features of the Global Cancer Monoclonal Antibodies Market

Market Size Estimates: Cancer monoclonal antibodies market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer monoclonal antibodies market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Cancer monoclonal antibodies market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, end uses, and regions for the cancer monoclonal antibodies market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer monoclonal antibodies market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cancer monoclonal antibodies market size?

Answer: The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030.

Q2. What is the growth forecast for cancer monoclonal antibodies market?

Answer: The global cancer monoclonal antibodies market is expected to grow with a CAGR of 12.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cancer monoclonal antibodies market?

Answer: The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.

Q4. What are the major segments for cancer monoclonal antibodies market?

Answer: The future of the cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets.

Q5. Who are the key cancer monoclonal antibodies market companies?

Answer: Some of the key cancer monoclonal antibodies companies are as follows:

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie

Q6. Which cancer monoclonal antibodies market segment will be the largest in future?

Answer: Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.

Q7. In cancer monoclonal antibodies market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer monoclonal antibodies market by type (humanized, human, chimeric, and murine), application (blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, and others), end use (hospitals, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Monoclonal Antibodies Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Monoclonal Antibodies Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Monoclonal Antibodies Market by Type
    • 3.3.1: Humanized
    • 3.3.2: Human
    • 3.3.3: Chimeric
    • 3.3.4: Murine
  • 3.4: Global Cancer Monoclonal Antibodies Market by Application
    • 3.4.1: Blood Cancer
    • 3.4.2: Breast Cancer
    • 3.4.3: Lung Cancer
    • 3.4.4: Melanoma
    • 3.4.5: Colorectal Cancer
    • 3.4.6: Liver Cancer
    • 3.4.7: Others
  • 3.5: Global Cancer Monoclonal Antibodies Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Research Institutes
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Monoclonal Antibodies Market by Region
  • 4.2: North American Cancer Monoclonal Antibodies Market
    • 4.2.2: North American Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.3: European Cancer Monoclonal Antibodies Market
    • 4.3.1: European Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.3.2: European Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.4: APAC Cancer Monoclonal Antibodies Market
    • 4.4.1: APAC Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.4.2: APAC Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.5: ROW Cancer Monoclonal Antibodies Market
    • 4.5.1: ROW Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.5.2: ROW Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Type
    • 6.1.2: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Application
    • 6.1.3: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Region
  • 6.2: Emerging Trends in the Global Cancer Monoclonal Antibodies Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Monoclonal Antibodies Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Monoclonal Antibodies Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Bristol Myers Squibb
  • 7.3: Merck
  • 7.4: GlaxoSmithKline
  • 7.5: Johnson & Johnson
  • 7.6: Amgen
  • 7.7: Novartis
  • 7.8: AstraZeneca
  • 7.9: Eli Lilly
  • 7.10: AbbVie